
Conference Coverage
about 1 month ago
Acalabrutinib-Venetoclax Combos Improve QOL, Safety by Age in CLLabout 1 month ago
Tec-Dara Closes Survival Gap in High-Risk MM: Rahul Banerjee, MDLatest Content

Student Mental Health, Success Tied to Future Health and Affordability

Less Chemo, Similar Survival in Pediatric Orbital Rhabdomyosarcoma

Ochsner Health, Paradigm Health Partnership Expands Clinical Trial Access Across the Gulf South

Mobile Integrated Health Valuable in Heart Failure, but Payment Lags

Contributor: The Deadly Gap in the Charity Care System

Shorts










Center on Health Equity & Access
All News

The FDA has approved oveporexton (Orzeyful), the first orexin agonist for narcolepsy type 1, based on phase 3 data showing broad symptom improvement.

Lab abnormalities can emerge between visits, and pharmacists may be able to catch uncontrolled hematocrit, adherence issues, or access barriers early.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

FDA advisers overrode their own scientists to back 6 peptides for compounding, even as safety data remains thin and gray-market risks persist.

Basement membrane composition actively drives NSCLC invasion, metastasis, and treatment resistance, a review finds, rather than serving as passive scaffolding.

Fix cardiorenalmetabolic care gaps: define ownership, task-shift screening, boost uACR testing, and tackle obesity-driven equity barriers.

Based on these results, the investigators are extending their follow-up into adolescence.

Clinicians at a Chicago Population Health Roundtable say atopic dermatitis biologic therapy is delayed by several key obstacles.

County-level CRC mortality was higher in areas with limited broadband access, higher smoking rates, and rurality.

Intismeran autogene plus pembrolizumab significantly improved recurrence-free and distant metastasis-free survival compared with pembrolizumab alone in resected stage IIB-IV melanoma.
























